Turning Point and Libtayo steal some pre-Asco thunder
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
Novo bets against Crispr for amyloidosis
Novo moves into amyloidosis not long after Intellia made a splash here.
Merck joins Covid-19 pack with vaccine and antiviral deals
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Bavarian’s chance to draw a line under oncology
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
Admedus moves from one unlikely area to another
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
